Takeda Pharmaceutical Co ADR (NYSE:TAK) has a beta value of 0.57 and has seen 0.87 million shares traded in the recent trading session. The company, currently valued at $44.57B, closed the recent trade at $14.06 per share which meant it gained $0.01 on the day or 0.07% during that session. The TAK stock price is -7.25% off its 52-week high price of $15.08 and 10.6% above the 52-week low of $12.57. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.88 million shares traded. The 3-month trading volume is 2.25 million shares.
The consensus among analysts is that Takeda Pharmaceutical Co ADR (TAK) is Buy stock at the moment, with a recommendation rating of 2.06. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 3 have rated it as a Hold, with 2 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is 0.58.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Takeda Pharmaceutical Co ADR (NYSE:TAK) trade information
Sporting 0.07% in the green today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the TAK stock price touched $14.06 or saw a rise of 2.02%. Year-to-date, Takeda Pharmaceutical Co ADR shares have moved -1.47%, while the 5-day performance has seen it change -1.54%. Over the past 30 days, the shares of Takeda Pharmaceutical Co ADR (NYSE:TAK) have changed -5.32%. Short interest in the company has seen 8.42 million shares shorted with days to cover at 4.7.
Takeda Pharmaceutical Co ADR (TAK) estimates and forecasts
Figures show that Takeda Pharmaceutical Co ADR shares have underperformed across the wider relevant industry. The company’s shares have gained 6.92% over the past 6 months, with this year growth rate of -7.78%, compared to 17.60% for the industry. Revenue growth from the last financial year stood is estimated to be 10.70%.
2 analysts offering their estimates for the company have set an average revenue estimate of 7.24M for the current quarter. 2 have an estimated revenue figure of 7.69M for the next ending quarter.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -12.87% over the past 5 years. Earnings growth for 2024 is a modest -15.27% while over the next 5 years, the company’s earnings are expected to increase by 20.67%.
TAK Dividends
Takeda Pharmaceutical Co ADR is expected to release its next earnings report on 2024-Oct-31 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue. The forward dividend is 0.29 at a share yield of 2.08%. The company’s dividend yield has gone up over the past 12 months, with a 5 Year Average Dividend Yield of 4.7%.
Takeda Pharmaceutical Co ADR (NYSE:TAK)’s Major holders
Insiders own 0.01% of the company shares, while shares held by institutions stand at 2.31% with a share float percentage of 2.31%. Investors are also buoyed by the number of investors in a company, with Takeda Pharmaceutical Co ADR having a total of 340.0 institutions that hold shares in the company. The top two institutional holders are CAPITAL RESEARCH GLOBAL INVESTORS with over 13.13 million shares worth more than $169.86 million. As of 2024-06-30, CAPITAL RESEARCH GLOBAL INVESTORS held 0.8366% of shares outstanding.
The other major institutional holder is MONDRIAN INVESTMENT PARTNERS LTD, with the holding of over 7.74 million shares as of 2024-06-30. The firm’s total holdings are worth over $108.34 million and represent 0.4932% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are American Mutual Fund Inc and First Tr Exchange Traded Fd-First Tr Value Line Dividend Index. As of Jul 31, 2024, the former fund manager holds about 0.41% shares in the company for having 12.95 shares of worth $181.94 million while later fund manager owns 3.17 shares of worth $44.56 million as of Sep 30, 2024, which makes it owner of about 0.10% of company’s outstanding stock.
